PathAI

PathAI

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.pathai.com

Last Round

Series C

5/18/2021

Est. Valuation

$1.1B

Total Funding Raised

$255.2M

Company Overview

PathAI is a healthcare technology company that offers an artificial intelligence-powered research platform designed to enhance the accuracy and efficiency of cancer diagnosis and treatment.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Usage-Based SaaS, Data as a Service

AI Layer

Application

Keywords

AI pathologydigital pathologycomputational pathologydigital pathology platformdiagnostic AIbiomarker analysiscompanion diagnosticsCDxclinical trial supportwhole slide imagingWSIquantitative pathologydrug discoveryFDA cleared AItranslational researchtumor microenvironmentdermatopathology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PathAI Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

PathAI Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series C5/18/2021
Series B11/4/2019
Series A11/2/2017
Seed12/1/2016

Key People

Founding team and executive leadership

Andrew Beck

Co-founder And CEO

Founding Team

Brandon Eldredge

Chief Financial Officer

Executive Team

PathAI Investors

Notable investors and investment history

InvestorRounds
Refactor CapitalSeries A, Series C, Seed
Fairhaven CapitalSeed
Biospring PartnersSeries C
Merck Global Health Innovation FundSeries C, Series B
General CatalystSeries B, Series C, Series A
D1 Capital PartnersSeries C
Pillar VCSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2026

    Partnered with MedStar Health to deploy digital pathology platform.

  • Mar 10, 2026

    AISight, a Digital Pathology Image Management System, has been commercially deployed.

PathAI Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PathAI Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PathAI's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range266
Year Founded2016
Last Funding5/18/2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.